

Special Issue

Novel Therapeutic Strategies for Lung Cancer in the Era of Personalized Treatment

Message from the Guest Editors

Lung cancer still remains as the world's leading cause of cancer death. Clinical development of immune checkpoint inhibitors (ICIs) has dramatically changed the prognosis of patients with non-small cell lung cancer. Of note, for the first time in 30 years, immunotherapy has also shown a survival benefit in patients with small cell lung cancer. Despite these advantages, the identification of reliable biomarkers is critical in efforts to further identify a subset of patients that may benefit from immunotherapy. Moreover, a combination of ICIs with other treatments is now under investigation to extend their efficacy in lung cancer patients. Thus, the aim of this Special Issue is to highlight recent studies on therapeutic strategies and biomarker evaluation in lung cancer.

Guest Editors

Dr. Konstantinos Porpodis

Department of Pulmonary Medicine, General Hospital of Thessaloniki 'Georgios Papanikolaou', Aristotle University of Thessaloniki, 57010 Exohi Thessaloniki, Greece

Dr. Kelly Domvri

1. Department of Pathology, General Hospital of Thessaloniki 'Georgios Papanikolaou', Thessaloniki, Greece
2. Pulmonary Department, Aristotle University of Thessaloniki, George Papanikolaou Hospital, Thessaloniki, Greece

Deadline for manuscript submissions

closed (10 September 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/73733

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)